User profiles for Kurt W. Prins

Kurt Prins

University of Minnesota
Verified email at umn.edu
Cited by 1915

Dystrophin is a microtubule-associated protein

KW Prins, JL Humston, A Mehta, V Tate… - Journal of Cell …, 2009 - rupress.org
Cytolinkers are giant proteins that can stabilize cells by linking actin filaments, intermediate
filaments, and microtubules (MTs) to transmembrane complexes. Dystrophin is functionally …

Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis

KW Prins, JM Neill, JO Tyler, PM Eckman, S Duval - JACC: Heart Failure, 2015 - jacc.org
Objectives : This study sought to evaluate the effects of beta-blocker withdrawal in acute
decompensated heart failure (ADHF). Background : Published reports showed trends for either …

Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension

KW Prins, SL Archer, M Pritzker, L Rose… - The Journal of Heart and …, 2018 - Elsevier
… Author links open overlay panel Kurt W. Prins MD, PhD a , Stephen L. Archer MD b , Marc
Pritzker MD a , Lauren Rose BS a , E. Kenneth Weir MD a , Alok Sharma MD c , Thenappan …

Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease

KW Prins, L Rose, SL Archer, M Pritzker… - Journal of the …, 2019 - Am Heart Assoc
Background Patients with pulmonary hypertension caused by chronic lung disease (Group
3 PH ) have disproportionate right ventricle ( RV ) dysfunction, but the correlates and clinical …

The critical role of pulmonary arterial compliance in pulmonary hypertension

T Thenappan, KW Prins, MR Pritzker… - Annals of the …, 2016 - atsjournals.org
The normal pulmonary circulation is a low-pressure, high-compliance system. Pulmonary
arterial compliance decreases in the presence of pulmonary hypertension because of …

Treatment targets for right ventricular dysfunction in pulmonary arterial hypertension

SZ Prisco, T Thenappan, KW Prins - Basic to Translational Science, 2020 - jacc.org
Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. …

Repurposing medications for treatment of pulmonary arterial hypertension: what's old is new again

KW Prins, T Thenappan, EK Weir, R Kalra… - Journal of the …, 2019 - Am Heart Assoc
Pulmonary arterial hypertension (PAH) is a rare but lethal disorder caused by several
pathological changes in the pulmonary vasculature. There is endothelial cell dysfunction …

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis

KW Prins, S Duval, J Markowitz… - Pulmonary …, 2017 - journals.sagepub.com
Pulmonary hypertension (PH) complicating chronic obstructive pulmonary disease (COPD-PH)
and interstitial lung disease (ILD-PH) (World Health Organization [WHO] Group III PH) …

World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology

KW Prins, T Thenappan - Cardiology clinics, 2016 - cardiology.theclinics.com
Pulmonary hypertension (PH) is defined as mean pulmonary arterial pressure(PAP) measured
by right heart catheterization of 25 mm Hg or higher at rest. 1 The most recent World …

Macrophage–NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension

…, S Bonnet, S Provencher, KW Prins… - American journal of …, 2022 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) often results in death from right ventricular
failure (RVF). NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin …